Evidence map›Paper›PMID 35411948›Full record

ArticleThe Journal of pathology2022

Recurrent WWTR1 S89W mutations and Hippo pathway deregulation in clear cell carcinomas of the cervix.

Sarah H Kim, Thais Basili, Higinio Dopeso, Arnaud Da Cruz Paula, Rui Bi, Shirin Issa Bhaloo, Fresia Pareja, Qing Li, Edaise M da Silva, Yingjie Zhu and 18 more

Open access · bronzeAbstract read
In one paragraph

Article in The Journal of pathology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

28 authors at 4 institutions in 5 countries.

Sarah H Kim *Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Thais Basili *Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Higinio Dopeso *Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Arnaud Da Cruz Paula *Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rui BiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Shirin Issa BhalooDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Fresia ParejaDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Qing LiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Edaise M da SilvaDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Yingjie ZhuDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Timothy HoangDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Pier SelenicaDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Rajmohan MuraliDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Eric ChanMolecular Cytology Core Facility, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Michelle WuDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Fatemeh DerakhshanDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Ana MaroldiDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Etta HanlonDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Carlos Gil FerreiraOncoclinicas Institute for Research and Education, Sao Paulo, Brazil.
Jose Roberto Lapa E SilvaFederal University of Rio de Janeiro, Rio de Janeiro, Brazil.
Nadeem R Abu-RustumDepartment of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Dmitriy ZamarinDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Sarat ChandarlapatyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Cathleen MatraiDepartment of Pathology, Weill Cornell Medical Center, New York, NY, USA.
Ju-Yoon YoonDepartment of Pathology, St Michael's Hospital, Unity Health Toronto, Toronto, Canada.
Jorge S Reis-FilhoDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-2969-3173
Kay J ParkDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Britta WeigeltDepartment of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9927-1270
Memorial Sloan Kettering Cancer Center · USUniversidade Federal do Rio de Janeiro · BRCornell University · USSt. Michael's Hospital · CA

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4M
Targeting Polθ to Overcome PARP Inhibitor Resistance in Homologous Recombination Deficient Breast CancerP50CA247749 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Simon N. Powell · 2020 to 2026
$16.3M
MSK Paul Calabresi Career Development Award for Clinical OncologyK12CA184746 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Omar Abdel-Wahab, Simon N. Powell · 2015 to 2026
$8.3M
NCI NIH HHS K12 CA184746NCI NIH HHS P30 CA008748NCI NIH HHS P30-CA008748NCI NIH HHS P50 CA247749NCI NIH HHS P50 CA247749 01NIH HHS K12 CA184746
6 · The paper itself

Abstract

Clear cell carcinoma (CCC) of the cervix (cCCC) is a rare and aggressive type of human papillomavirus (HPV)-negative cervical cancer with limited effective treatment options for recurrent or metastatic disease. Historically, CCCs of the lower genital tract were associated with in utero diethylstilbestrol exposure; however, the genetic landscape of sporadic cCCCs remains unknown. Here we sought to define the molecular underpinning of cCCCs. Using a combination of whole-exome, targeted capture, and RNA-sequencing, we identified pathogenic genetic alterations in the Hippo signaling pathway in 50% (10/20) of cCCCs, including recurrent WWTR1 S89W somatic mutations in 40% (4/10) of the cases harboring mutations in the Hippo pathway. Irrespective of the presence or absence of Hippo pathway genetic alterations, however, all primary cCCCs analyzed in this study (n = 20) harbored features of Hippo pathway deregulation at the transcriptomic and protein levels. In vitro functional analysis revealed that expression of the WWTR1 S89W mutation leads to reduced binding of TAZ to 14-3-3, promoting constitutive nuclear translocation of TAZ and Hippo pathway repression. WWTR1 S89W expression was found to lead to acquisition of oncogenic behavior, including increased proliferation, migration, and colony formation in vitro as well as increased tumorigenesis in vivo, which could be reversed by targeted inhibition of the TAZ/YAP1 complex with verteporfin. Finally, xenografts expressing WWTR1 S89W displayed a shift in tumor phenotype, becoming more infiltrative as well as less differentiated, and were found to be composed of cells with conspicuous cytoplasmic clearing as compared to controls. Our results demonstrate that Hippo pathway alterations are likely drivers of cCCCs and likely contribute to the clear cell phenotype. Therapies targeting this pathway may constitute a new class of treatment for these rare, aggressive tumors. © 2022 The Pathological Society of Great Britain and Ireland.

Indexed as

Hippo Signaling PathwayTrans-ActivatorsCarcinogenesisCervix UteriFemaleHumansIntracellular Signaling Peptides and ProteinsMutationSignal TransductionTranscriptional Coactivator with PDZ-Binding Motif ProteinsIntracellular Signaling Peptides and ProteinsTrans-ActivatorsTranscriptional Coactivator with PDZ-Binding Motif ProteinsWWTR1 protein, humancervixclear cellHippo pathwaymassively parallel sequencingWWTR1

Identifiers

PMID35411948
PMCPMC9881397
OpenAlexW4223464541

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.